CHICAGO, and ANN ARBOR, Mich., June 3, 2011 /PRNewswire/ —
Everist Genomics today announced updated results from a study of
its OncoDefender-CRC assay, a molecular prognostic test for
early-stage colorectal cancer patients, will be presented at the
2011 American Society of Clinical Oncology (ASCO) Annual Meeting,
which will be held June 3-7, 2011, in Chicago.
(Logo: http://photos.prnewswire.com/prnh/20110110/NY26865LOGO)
OncoDefender-CRC examines expression levels of a panel of genes
extracted from formalin-fixed paraffin-embedded cancer tissue taken
at the time of surgery, and uses a proprietary computer-generated
decision rule to stratify patients into ‘high-risk’ and ‘low-risk’
categories for assessing likelihood of recurrence.
Accurately identifying Stage I/II colorectal cancer patients who
are at risk of recurrence represents a significant unmet medical
need as mortality rates for early stage disease are higher than
generally realized. “About one in seven patients with Stage I and
one in three patients with Stage II colorectal cancer will
ultimately experience a recurrence,” said Peter F. Lenehan, M.D.,
Ph.D. Chief Medical Officer of Everist Genomics. “In this
sub-population of patients who recur, the associated mortality
rates are 50 percent and 80 percent, respectively.”
The study confirmed that OncoDefender-CRC was able to
differentiate those patients at high risk from those at low risk
for cancer recurrence within 3 years after potentially curative
surgery more accurately than assessments based on National
Comprehensive Cancer Network (NCCN) Guidelines, widely accepted as
providing “best practices” in oncology. The study included
patient samples from four international sites.
For stages I/II colorectal cancer (n=115), OncoDefender-CRC
correctly classified 32/46 cases of recurrence and 38/69 cases of
non-recurrence (sensitivity 70%, specif
‘/>”/>
